TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens

Published 2011 View Full Article

Authors

Keywords

Journal

MOLECULAR CANCER THERAPEUTICS

Volume 11, Issue 3, Pages 700-709

Publisher

American Association for Cancer Research (AACR)

Online

2011-12-22

DOI

10.1158/1535-7163.mct-11-0762

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

MOLECULAR CANCER THERAPEUTICS

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Become a Peeref-certified reviewer